MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Bio-Techne Corp

Закрыт

СекторЗдравоохранение

60.55 2.28

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

58.43

Макс.

61.03

Ключевые показатели

By Trading Economics

Доход

-40M

-18M

Продажи

783K

317M

P/E

Средняя по отрасли

134.609

37.257

Прибыль на акцию

0.53

Дивидендная доходность

0.51

Рентабельность продаж

-5.577

Сотрудники

3,100

EBITDA

-61M

6.4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+12.43% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.51%

2.94%

Следующий отчет о доходах

29 окт. 2025 г.

Дата следующей выплаты дивидендов

21 нояб. 2025 г.

Следующая эксдивидендная дата

10 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

750M

9.6B

Предыдущая цена открытия

58.27

Предыдущая цена закрытия

60.55

Новостные настроения

By Acuity

50%

50%

183 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Bio-Techne Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 окт. 2025 г., 16:58 UTC

Отчет

BMW Trims 2025 View, Citing Weaker Performance in China

7 окт. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 окт. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 окт. 2025 г., 23:19 UTC

Обсуждения рынка

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 окт. 2025 г., 22:50 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

7 окт. 2025 г., 22:50 UTC

Обсуждения рынка

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 окт. 2025 г., 22:40 UTC

Обсуждения рынка

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 окт. 2025 г., 21:56 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

7 окт. 2025 г., 21:56 UTC

Обсуждения рынка

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

7 окт. 2025 г., 20:44 UTC

Популярные акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 окт. 2025 г., 19:42 UTC

Обсуждения рынка

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 окт. 2025 г., 19:23 UTC

Приобретения, слияния, поглощения

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 окт. 2025 г., 19:07 UTC

Обсуждения рынка

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 окт. 2025 г., 19:02 UTC

Обсуждения рынка

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

7 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

7 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 окт. 2025 г., 16:15 UTC

Обсуждения рынка

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 окт. 2025 г., 16:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

7 окт. 2025 г., 15:37 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

7 окт. 2025 г., 15:37 UTC

Обсуждения рынка

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 окт. 2025 г., 15:33 UTC

Обсуждения рынка

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 окт. 2025 г., 15:25 UTC

Обсуждения рынка

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 окт. 2025 г., 15:15 UTC

Обсуждения рынка

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 окт. 2025 г., 15:04 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

7 окт. 2025 г., 15:04 UTC

Обсуждения рынка

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 окт. 2025 г., 14:56 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

7 окт. 2025 г., 14:56 UTC

Обсуждения рынка

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 окт. 2025 г., 14:52 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение c конкурентами

Изменение цены

Bio-Techne Corp Прогноз

Целевая цена

By TipRanks

12.43% рост

Прогноз на 12 месяцев

Средняя 66.55 USD  12.43%

Максимум 75 USD

Минимум 53 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Bio-Techne Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

11

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

49.67 / 50.24Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Strong Bearish Evidence

Настроения

By Acuity

183 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat